Latest Breaking News On - Alfred sandrock - Page 13 : comparemela.com
Biogen defends Alzheimer s drug approval, reports $2 mln in early sales
reuters.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from reuters.com Daily Mail and Mail on Sunday newspapers.
Biogen defends Alzheimer s drug approval, reports $2 million in early sales
business-standard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from business-standard.com Daily Mail and Mail on Sunday newspapers.
Biogen says uptake on new Alzheimer s drug slower than expected
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
> Nachricht Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis
Nachrichtenquelle: globenewswire | 13.07.2021, 01:00 | 91 | 0
Orelabrutinib is a Phase 2 oral small molecule Bruton’s tyrosine kinase inhibitor with high selectivity and the ability to cross the blood-brain barrier
InnoCare to receive a $125 million upfront payment and is eligible to receive potential development and commercial milestone payments CAMBRIDGE, Mass. and BEIJING, July 12, 2021 (GLOBE NEWSWIRE) Biogen Inc. (Nasdaq: BIIB) and InnoCare Pharma Limited (HKEX: 09969) today announced that they have entered into a license and collaboration agreement for orelabrutinib, an oral small molecule Bruton’s tyrosine kinase
(1)
Orelabrutinib is a Phase 2 oral small molecule Bruton s tyrosine kinase inhibitor with high selectivity and the ability to cross the blood-brain barrier
InnoCare to receive a $125 million upfront payment and is eligible to receive potential development and commercial milestone payments
CAMBRIDGE, Mass. and BEIJING, July 12, 2021(Nasdaq: BIIB) and InnoCare Pharma Limited (HKEX: 09969) today announced that they have entered into a license and collaboration agreement for orelabrutinib, an oral small molecule Bruton s tyrosine kinase inhibitor (BTKi) for the potential treatment of multiple sclerosis (MS). Orelabrutinib is a covalent BTKi with high selectivity and the ability to cross the blood-brain barrier, and is currently being studied in a multi-country, placebo-controlled Phase 2 trial in relapsing-remitting MS.